Bone Biologics Corporation (BBLG)

Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BURLINGTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone...

Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1

BURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the...

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

BURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a...

Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months

BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a...

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Bone Biologics Announces Closing of $5.0 Million Public Offering

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Bone Biologics Announces Pricing of $5.0 Million Public Offering

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Bone Biologics Files Patent Application for Bone Regeneration Technology

Bone Biologics Corporation (“Bone Biologics” or the “Company) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Bone Biologics Announces 1-for-6 Reverse Stock Split

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation (“Bone Biologics” or the “Company”...

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion...

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933